PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
Pharma-Bio Serv, Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026
- Market cap
- $11.00M
- P/E (TTM)
- 48.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
32.3%+1.4 pts over 5 years
Operating margin
-7.1%−17.4 pts over 5 years
Net margin
-1.1%−10.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -5.3% | -22.6% | -16.0% | -9.1% | |
| Gross profit | +15.7% | -15.8% | -15.3% | -9.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -1.2% | 9.5% | -0.8% | |
| Return on assets | -1.1% | 7.3% | -0.7% | |
| Current ratio | 10.02 | 7.54 | 7.70 | |
| Capex to revenue | 9.3% | 0.3% | 0.1% | |
| Diluted shares | 23M | 23M | 23M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pharma-Bio Serv generated $4.07M from operations and spent $10.73M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
Generated
$4.07M
Used
$10.73M
Capital expenditure$203.75K2%Dividends$10.34M96%Share buybacks$185.01K2%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1.1%
×Asset turnover0.60×
×Equity multiplier1.17×
=Return on equity, FY2025-0.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1.1% | 0.60× | 1.17× | -0.8% |
| FY2024 | -8.2% | 0.53× | 1.21× | -5.2% |
| FY2023 | 7.7% | 0.84× | 1.24× | 8.0% |
| FY2022 | 5.2% | 0.87× | 1.26× | 5.7% |
| FY2021 | -10.4% | 0.75× | 1.29× | -10.0% |
| FY2020 | 9.5% | 0.76× | 1.31× | 9.5% |
| FY2019 | 10.7% | 0.75× | 1.27× | 10.2% |
| FY2018 | 7.2% | 0.75× | 1.16× | 6.2% |
| FY2017 | -10.6% | 0.57× | 1.09× | -6.6% |
| FY2016 | -1.3% | 0.81× | 1.10× | -1.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$100.46K
- Cash generatingOperating cash flow above zero-$214.89K
- Return on assets improvedROA up on the prior year-3.9% → -0.6%
- Earnings backed by cashOperating cash flow above net income-$214.89K vs -$100.46K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.32 → 7.70
- No dilutionShare count did not rise23M → 23M
- Gross margin improvedGross margin up on the prior year26.46% → 32.33%
- More efficientAsset turnover rose0.48 → 0.55